Increased spironolactone in advanced heart failure: Effect of doses greater than 25 mg/day on plasma potassium concentration

CardioRenal Medicine

Volumn 3, Issue 1, 2013, Pages 1-6

  Shchekochikhin, Dmitry ^a   Lindenfeld, Joann ^b   Schrier, Robert ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Hyperkalemia; Spironolactone

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CHLORIDE; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; POTASSIUM; SODIUM; SPIRONOLACTONE; TORASEMIDE; UREA;

ADD ON THERAPY; ADULT; ARTICLE; CARDIAC PATIENT; CHLORIDE BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIURETIC THERAPY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEART FAILURE; HUMAN; KALIURESIS; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NATRIURESIS; NEW YORK HEART ASSOCIATION CLASS; OUTPATIENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

EID: 84879804143     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000346447     Document Type: Article

References (15)

1. Pitt B, Zannad F, Remme WJ, et al; Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
3. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASISHF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
4. The RALES Investigators: Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-907.
5. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP: Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010; 122: 265-272.
6. Juurlink D, Mamdani M, Lee DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
7. Li W, Struthers AD, Fahey T, Watson AD, MacDonald TM: Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010; 340:c1768.
8. Schrier RW: Aldosterone 'escape' versus 'breakthrough'. Nat Rev Nephrol 2010; 6: 61.
9. Jencks SF, Williams MV, Coleman EA: Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009; 360: 1418-1428.
10. Schrier RW: Decreased effective blood volume in edematous disorders: what does this mean? J Am Soc Nephrol 2007; 18: 2028-2031.
11. Bansal S, Lindenfeld JA, Schrier RW: Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2009; 2: 370-376.
12. Ginès P, Schrier RW: Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-1290.
13. Braunwald E, Plauth HW Jr, Morrow AG: A method for the detection and quantification of impaired sodium excretion. Circulation 1965; 32: 223-231.
14. Hensen J, Abraham WT, Dürr JA, Schrier RW: Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol 1991; 11: 441-446.
15. Van Vliet AA, Donker AJ, Nauta JJ, et al: Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993; 71: 21A-28A.